SG10201510324YA - Process for preparing nucleoside prodrugs - Google Patents

Process for preparing nucleoside prodrugs

Info

Publication number
SG10201510324YA
SG10201510324YA SG10201510324YA SG10201510324YA SG10201510324YA SG 10201510324Y A SG10201510324Y A SG 10201510324YA SG 10201510324Y A SG10201510324Y A SG 10201510324YA SG 10201510324Y A SG10201510324Y A SG 10201510324YA SG 10201510324Y A SG10201510324Y A SG 10201510324YA
Authority
SG
Singapore
Prior art keywords
nucleoside prodrugs
preparing nucleoside
preparing
prodrugs
nucleoside
Prior art date
Application number
SG10201510324YA
Other languages
English (en)
Inventor
Christopher Mcguigan
Fabrizio Pertusati
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201510324Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of SG10201510324YA publication Critical patent/SG10201510324YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
SG10201510324YA 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs SG10201510324YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds

Publications (1)

Publication Number Publication Date
SG10201510324YA true SG10201510324YA (en) 2016-01-28

Family

ID=49622844

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201510324YA SG10201510324YA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
SG11201503750YA SG11201503750YA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
SG10201510322UA SG10201510322UA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201503750YA SG11201503750YA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
SG10201510322UA SG10201510322UA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Country Status (28)

Country Link
US (3) US10005810B2 (ja)
EP (3) EP3235824B1 (ja)
JP (5) JP2016506371A (ja)
KR (1) KR20150103669A (ja)
CN (2) CN104903339A (ja)
AU (1) AU2013346515B2 (ja)
CA (1) CA2891266C (ja)
CL (1) CL2015001307A1 (ja)
CY (2) CY1119161T1 (ja)
DK (2) DK3235824T3 (ja)
EA (1) EA028871B1 (ja)
ES (3) ES2627195T3 (ja)
HK (1) HK1210784A1 (ja)
HR (2) HRP20170791T1 (ja)
HU (2) HUE033335T2 (ja)
IL (1) IL238792A (ja)
IN (1) IN2015DN04090A (ja)
LT (2) LT3235824T (ja)
MX (1) MX2015006195A (ja)
MY (1) MY176133A (ja)
NZ (1) NZ708177A (ja)
PH (1) PH12015501090B1 (ja)
PL (2) PL3235824T3 (ja)
PT (2) PT3235824T (ja)
RS (2) RS56038B1 (ja)
SG (3) SG10201510324YA (ja)
SI (2) SI3235824T1 (ja)
WO (1) WO2014076490A1 (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
MY176133A (en) * 2012-11-16 2020-07-24 Nucana Biomed Ltd Process for preparing nucleoside prodrugs
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
EP3074411A2 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucleotides for the treatment of liver cancer
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
MX2016015629A (es) 2014-06-25 2017-08-02 Nucana Biomed Ltd Formulacion que comprende un profarmaco de gemcitabina.
EP3160978B1 (en) * 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
BR112017001847A2 (pt) * 2014-07-31 2018-02-27 Sandoz Ag processo para a preparação de um composto de fórmula (i), mistura, composição e composto de fórmula (ii)
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
EP3274356A1 (en) 2015-03-26 2018-01-31 Química Sintética, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106539810B (zh) * 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
EA037248B1 (ru) * 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
WO2017090264A1 (ja) * 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
EP3386998B1 (en) * 2015-12-11 2021-11-10 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
KR20190043602A (ko) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
AU2017378959B2 (en) 2016-12-23 2021-09-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
GEP20237457B (en) 2017-02-01 2023-01-10 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
CN111989335B (zh) 2018-06-12 2023-06-13 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
KR20040094692A (ko) 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
KR20110120886A (ko) 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
JP5872539B2 (ja) * 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
JP5937073B2 (ja) * 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
GEP20156313B (en) * 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
WO2012088155A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
CA2828326C (en) * 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
AU2012223528A1 (en) * 2011-03-02 2013-10-24 Joseph M. Fayad Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
AU2012323937A1 (en) * 2011-10-14 2014-06-05 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
MY176133A (en) * 2012-11-16 2020-07-24 Nucana Biomed Ltd Process for preparing nucleoside prodrugs
EP3013340B9 (en) * 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
US9862743B2 (en) * 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3074001A1 (en) * 2013-11-27 2016-10-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Piperidine and piperazine derivatives and their use in treating viral infections and cancer
EP3074411A2 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucleotides for the treatment of liver cancer
MX2016015629A (es) 2014-06-25 2017-08-02 Nucana Biomed Ltd Formulacion que comprende un profarmaco de gemcitabina.
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
MX2020009154A (es) 2015-05-14 2022-03-08 NuCana plc Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
EA037248B1 (ru) 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
EP3386998B1 (en) 2015-12-11 2021-11-10 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201805184TA (en) 2015-12-23 2018-07-30 NuCana plc Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy

Also Published As

Publication number Publication date
SG11201503750YA (en) 2015-06-29
SI3150616T1 (sl) 2017-08-31
PT3235824T (pt) 2019-05-30
CA2891266C (en) 2020-12-08
RS58849B1 (sr) 2019-07-31
JP2019196360A (ja) 2019-11-14
EP3235824A1 (en) 2017-10-25
SI3235824T1 (sl) 2019-08-30
ES2627195T3 (es) 2017-07-27
EP2920192A1 (en) 2015-09-23
EP3235824B1 (en) 2019-03-27
PL3235824T3 (pl) 2019-09-30
HRP20170791T1 (hr) 2017-08-25
PT3150616T (pt) 2017-06-09
MY176133A (en) 2020-07-24
HUE033335T2 (en) 2017-11-28
CA2891266A1 (en) 2014-05-22
IN2015DN04090A (ja) 2015-10-09
EP3150616B1 (en) 2017-05-10
DK3235824T3 (da) 2019-05-20
CY1119161T1 (el) 2018-02-14
EP2920192B1 (en) 2017-02-22
HUE044605T2 (hu) 2019-11-28
AU2013346515A1 (en) 2015-06-04
HRP20190831T1 (hr) 2019-08-23
CL2015001307A1 (es) 2015-12-11
RS56038B1 (sr) 2017-09-29
KR20150103669A (ko) 2015-09-11
PH12015501090A1 (en) 2015-07-27
LT3150616T (lt) 2017-07-25
ES2725491T3 (es) 2019-09-24
WO2014076490A1 (en) 2014-05-22
JP2023052536A (ja) 2023-04-11
SG10201510322UA (en) 2016-01-28
ES2618732T3 (es) 2017-06-22
CN104903339A (zh) 2015-09-09
AU2013346515B2 (en) 2017-05-25
US10005810B2 (en) 2018-06-26
JP2016506371A (ja) 2016-03-03
EA028871B1 (ru) 2018-01-31
IL238792A (en) 2017-09-28
EA201590955A1 (ru) 2015-08-31
JP2021020919A (ja) 2021-02-18
US20150291650A1 (en) 2015-10-15
PL3150616T3 (pl) 2017-09-29
CN111592577A (zh) 2020-08-28
DK3150616T3 (en) 2017-06-06
PH12015501090B1 (en) 2015-07-27
BR112015011155A2 (pt) 2017-07-11
IL238792A0 (en) 2015-06-30
LT3235824T (lt) 2019-07-10
CY1121663T1 (el) 2020-07-31
US20180273575A1 (en) 2018-09-27
EP3150616A1 (en) 2017-04-05
MX2015006195A (es) 2015-12-08
US20220033433A1 (en) 2022-02-03
JP2018009000A (ja) 2018-01-18
HK1210784A1 (en) 2016-05-06
US11040997B2 (en) 2021-06-22
NZ708177A (en) 2017-08-25

Similar Documents

Publication Publication Date Title
HK1210784A1 (en) Process for preparing nucleoside prodrugs
ZA201500603B (en) Process
GB201216921D0 (en) Process
HK1207384A1 (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d- ribofuranosyl nucleoside compounds 2--2--2--d-
IL227872A0 (en) A process for the preparation of n-converted phenylhydroxylamines
GB201207997D0 (en) Process
SG11201500381TA (en) Process
GB201214326D0 (en) Process
EP2887941A4 (en) PROCESS FOR THE PREPARATION OF ANTIVIRAL COMPOUNDS
EP2852660A4 (en) PROCESS
ZA201502344B (en) Process
EP2855433A4 (en) PROCESS FOR THE PREPARATION OF DIHALOPYRIDINES
EP2819995A4 (en) PROCESS FOR THE PREPARATION OF 3-METHYLSULFONYLPROPIONITRIL
GB201219224D0 (en) Process
GB201318062D0 (en) Process
GB201317561D0 (en) Process
EP2938605A4 (en) PROCESS FOR THE PREPARATION OF AMORPHOUS CABAZITAXEL
IL233626A0 (en) A process for the preparation of chloroamines
IL233388A (en) Process for the preparation of acetanilides
EP2831054A4 (en) IMPROVED PROCESS FOR THE PRODUCTION OF (S) -EQUOL
GB201316604D0 (en) Process
HK1206043A1 (en) Process
GB201223071D0 (en) Process
GB201222686D0 (en) Process
GB201220746D0 (en) Process